ST. LOUIS, Sept. 12 /PRNewswire/ -- Prolog Ventures, a venture capital firm specializing in life science investments, today announced that Dan Broderick has joined the firm as its fourth partner. Broderick brings more than 20 years of experience in early-stage investing, venture fund management, and technology commercialization.
Before coming to Prolog, Broderick was a managing director at Mason Wells in Milwaukee, WI, where he served on its board of directors and management committee and managed the Mason Wells Biomedical Fund -- the firm's first venture capital fund. Prior to this, he spent 18 years at the Mayo Clinic in Rochester, MN, where he served as director of technology commercialization for 12 years and co-launched the clinic's corporate venture capital fund.
"Dan's extensive industry experience and deal flow connections further strengthen Prolog's expertise in early-stage life science investing," said Ilya Nykin, managing director of Prolog. "He was involved in the creation, financing, and growth of more than 20 venture-backed companies in Prolog's core areas of focus, most of them early-stage. Having Dan on Prolog's team is a great boost to our mission of translating life science breakthroughs into successful ventures."
Broderick's professional accomplishments have prompted a number of prominent industry boards and advisory panels to seek his involvement. He is a member of the board of directors of the National Venture Capital Association and the chair of its Research Committee; a trustee of both the Medical College of Wisconsin and the University of Wisconsin-Milwaukee Research Foundations; a member of the University of Minnesota Business Development Advisory Board; and a charter member of the venture capital advisory board of BioGenerator, a St. Louis nonprofit seed-capital investment fund.
"Not only is Dan an astute investor, but he is also a long-time
colleague. We have an excellent track record of working together," sa
|SOURCE Prolog Ventures|
Copyright©2007 PR Newswire.
All rights reserved